摘要
目的探讨亮丙瑞林微球治疗子宫内膜异位症患者的临床效果。方法80例子宫内膜异位症患者,采用简单随机化法分为研究组和对照组,每组40例。两组均实施常规护理,对照组采用孕三烯酮胶囊治疗,研究组在对照组基础上采用亮丙瑞林微球治疗。比较两组治疗效果,治疗前后的疼痛评分及生活质量评分、血清糖类抗原125(CA125)和血管内皮生长因子(VEGF)水平、雌激素[孕酮(P)、卵泡刺激素(FSH)、雌二醇(E_(2))、促黄体生成素(LH)]水平及不良反应发生情况。结果研究组治疗总有效率97.5%明显高于对照组的85.0%,差异具有统计学意义(P<0.05)。治疗后,两组视觉模拟评分法(VAS)评分低于本组治疗前,健康状况调查简表(SF-36)评分高于本组治疗前,且研究组VAS评分(2.06±0.64)分低于对照组的(4.85±0.95)分,SF-36评分(92.67±8.82)分高于对照组的(72.88±6.30)分,差异具有统计学意义(P<0.05)。治疗后,两组P、FSH、E2水平均明显低于本组治疗前,LH水平明显高于本组治疗前,且研究组P、FSH、E_(2)水平分别为(16.53±6.51)nmol/L、(4.64±1.06)U/L、(240.37±38.20)pmol/L,低于对照组的(21.38±6.85)nmol/L、(6.35±1.28)U/L、(267.39±40.07)pmol/L,LH水平(12.98±1.67)U/L高于对照组的(9.62±1.50)U/L,差异具有统计学意义(P<0.05)。治疗后,两组血清CA125和VEGF水平均明显低于本组治疗前,且研究组血清CA125和VEGF水平分别为(20.15±1.94)U/ml、(106.58±21.55)ng/L低于对照组的(27.38±2.06)U/ml、(139.62±25.64)ng/L,差异有统计学意义(P<0.05)。研究组治疗期间药物不良反应发生率10.0%低于对照组的27.5%,差异有统计学意义(P<0.05)。结论亮丙瑞林微球治疗子宫内膜异位症患者临床疗效显著,能够有效缓解患者痛疼,降低患者血清炎症因子水平,改善雌激素含量,提高患者生活质量,且安全性良好。
Objective To discuss the clinical effect of Lupron Depot in the treatment of endometriosis patients.Methods A total of 80 patients with endometriosis were divided into research group and control group by simple randomization method,with 40 cases in each group.Usual care was given to both groups.The control group was treated with pregntrienone capsules,and the research group was treated with Lupron Depot on the basis of the control group.Both groups were compared in terms of therapeutic effect,pain score,quality of life score,serum carbohydrate antigen 125(CA125)and vascular endothelial growth factor(VEGF)levels,estrogen[progesterone(P),follicle stimulating hormone(FSH),estradiol(E_(2)),luteinizing hormone(LH)]levels before and after treatment,and the occurrence of adverse reactions.Results The total effective rate of 97.5%in the research group was significantly higher than that of 85.0%in the control group,and the difference was statistically significant(P<0.05).After treatment,visual analogue scale(VAS)score in the two groups was lower than that before treatment in this group,and 36-item short-form health survey(SF-36)score was higher than that before treatment in this group;VAS score of(2.06±0.64)points in the research group was lower than that of(4.85±0.95)points in the control group;SF-36 score of(92.67±8.82)points in the research group was higher than that of(72.88±6.30)points in the control group;the differences were statistically significant(P<0.05).After treatment,P,FSH and E_(2) levels in both groups were significantly lower than those before treatment in this group,while LH level was significantly higher than that before treatment in this group;the levels of P,FSH and E2 were(16.53±6.51)nmol/L,(4.64±1.06)U/L and(240.37±38.20)pmol/L in the research group,which were lower than those of(21.38±6.85)nmol/L,(6.35±1.28)U/L and(267.39±40.07)pmol/L in the control group;LH level of(12.98±1.67)U/L in the research group was higher than that of(9.62±1.50)U/L in the control group;the differences were stat
作者
宁桂兰
NING Gui-lan(Department of Obstetrics and Gynecology,Shaowu Municipal Hospital,Shaowu 354000,China)
出处
《中国现代药物应用》
2023年第13期124-127,共4页
Chinese Journal of Modern Drug Application
